U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C17H11ClNO2S.Ca
Molecular Weight 697.663
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENTIAZAC CALCIUM

SMILES

[Ca++].[O-]C(=O)CC1=C(N=C(S1)C2=CC=CC=C2)C3=CC=C(Cl)C=C3.[O-]C(=O)CC4=C(N=C(S4)C5=CC=CC=C5)C6=CC=C(Cl)C=C6

InChI

InChIKey=WGCKYSZZBQAHJJ-UHFFFAOYSA-L
InChI=1S/2C17H12ClNO2S.Ca/c2*18-13-8-6-11(7-9-13)16-14(10-15(20)21)22-17(19-16)12-4-2-1-3-5-12;/h2*1-9H,10H2,(H,20,21);/q;;+2/p-2

HIDE SMILES / InChI
Molecular Formula Ca
Molecular Weight 40.078
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C17H11ClNO2S
Molecular Weight 328.793
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Fentiazac is a non-steroidal anti-inflammatory agent developed for the treatment of pain disorders. The drug was marketed under the name Norvedan, however, its current marketing status is unknown and supposed to be "discontinued".

Approval Year

Unknown
149124
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
NORVEDAN

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2670 ng/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3450 ng/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4080 ng/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1990 ng/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1500 ng/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1240 ng/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.4 mg/L
CLINICAL TRIAL
https://pubmed.ncbi.nlm.nih.gov/8447848/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4490 ng × h/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5200 ng × h/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5670 ng × h/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5770 ng × h/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5510 ng × h/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3400 ng × h/mL
CLINICAL TRIAL
doi:10.3109/00498258409151493
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7 h
CLINICAL TRIAL
https://pubmed.ncbi.nlm.nih.gov/8447848/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FENTIAZAC plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 2 times / day multiple, oral
Studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3325316/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3325316/
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (grade 3, 5.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3325316/
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Disc. AE: Itching, Skin eruption...
AEs leading to
discontinuation/dose reduction:
Itching (grade 2, 5%)
Skin eruption (grade 2, 5%)
Epigastric pain (grade 2, 5%)
Headache (grade 2, 5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Disc. AE: Epigastric pain, Gastric ulcer...
AEs leading to
discontinuation/dose reduction:
Epigastric pain (6%)
Gastric ulcer (3%)
Liver function test abnormal (9%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
AEs

AEs

AESignificanceDosePopulation
Rash grade 3, 5.3%
Disc. AE
200 mg 2 times / day multiple, oral
Studied dose
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3325316/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3325316/
Epigastric pain grade 2, 5%
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Headache grade 2, 5%
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Itching grade 2, 5%
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Skin eruption grade 2, 5%
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Gastric ulcer 3%
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Epigastric pain 6%
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
Liver function test abnormal 9%
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/6340972/
PubMed

PubMed

TitleDatePubMed
Topical NSAIDs for acute pain: a meta-analysis.
2004-05-17
Patents

Patents

JP2003515526A
470

Sample Use Guides

In Vivo Use Guide
6,44 mg/kg as a daily dose.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:47:27 GMT 2025
Edited
by admin
on Mon Mar 31 18:47:27 GMT 2025
Record UNII
87K2GQ2Q21
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FENTIAZAC CALCIUM
WHO-DD  
Common Name English
(4-(4-CHLOROPHENYL)-2-PHENYLTHIAZOL-5-YL)ACETIC ACID, CALCIUM SALT
Preferred Name English
Fentiazac calcium [WHO-DD]
Common Name English
5-THIAZOLEACETIC ACID, 4-(4-CHLOROPHENYL)-2-PHENYL-, CALCIUM SALT (2:1)
Common Name English
5-THIAZOLEACETIC ACID, 4-(4-CHLOROPHENYL)-2-PHENYL-, CALCIUM SALT
Common Name English
Code System Code Type Description
FDA UNII
87K2GQ2Q21
Created by admin on Mon Mar 31 18:47:28 GMT 2025 , Edited by admin on Mon Mar 31 18:47:28 GMT 2025
PRIMARY
ECHA (EC/EINECS)
288-435-4
Created by admin on Mon Mar 31 18:47:28 GMT 2025 , Edited by admin on Mon Mar 31 18:47:28 GMT 2025
PRIMARY
EVMPD
SUB02130MIG
Created by admin on Mon Mar 31 18:47:28 GMT 2025 , Edited by admin on Mon Mar 31 18:47:28 GMT 2025
PRIMARY
PUBCHEM
198620
Created by admin on Mon Mar 31 18:47:28 GMT 2025 , Edited by admin on Mon Mar 31 18:47:28 GMT 2025
PRIMARY
CAS
85721-24-0
Created by admin on Mon Mar 31 18:47:28 GMT 2025 , Edited by admin on Mon Mar 31 18:47:28 GMT 2025
PRIMARY
EPA CompTox
DTXSID80235035
Created by admin on Mon Mar 31 18:47:28 GMT 2025 , Edited by admin on Mon Mar 31 18:47:28 GMT 2025
PRIMARY
SMS_ID
100000086986
Created by admin on Mon Mar 31 18:47:28 GMT 2025 , Edited by admin on Mon Mar 31 18:47:28 GMT 2025
PRIMARY
Related Record Type Details
Structure of FENTIAZAC
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of FENTIAZAC
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966